Working… Menu

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors (SPINET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02683941
Recruitment Status : Active, not recruiting
First Posted : February 17, 2016
Last Update Posted : October 1, 2019
Information provided by (Responsible Party):

Brief Summary:

This is a Phase 3, prospective, multi-center, randomized, double-blind, study evaluating the efficacy and safety of LAN plus BSC versus placebo plus BSC for the treatment of well-differentiated, metastatic and/or unresectable, typical or atypical lung NETs.

This study contains two phases: the Double-Blind (DB) Phase, and the Open Label (OL) Extension Phase. The DB Phase includes: Screening, Baseline and Treatment period. The OL Extension Phase will consist of two periods: Treatment Period and Follow-Up Period.

The primary objective will be to compare the antitumour efficacy of Lanreotide Autogel/Depot 120 mg (LAN) plus Best Supportive Care (BSC) every 28 days versus placebo plus BSC, in terms of progression-free survival (PFS), measured by central review using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria, every 12 weeks, in subjects with unresectable and/or metastatic well differentiated, typical or atypical lung neuroendocrine tumours.

Recent updates of NCCN & ENETS guidelines recommend SSA in first line for the treatment of locoregional unresectable or metastatic lung NETs as an option beyond 'observation'. Consequently, it was decided to prematurely stop the recruitment in the SPINET study and to transition subjects still treated in the double-blind phase to the OL treatment phase following the country approval of Amendment #5.

The new aim of this Phase 3, multicenter, prospective, randomized placebo-controlled clinical study is to describe the antitumor efficacy and safety of Lanreotide Autogel/Depot 120 mg (LAN) plus Best Supportive Care (BSC) in subjects with well-differentiated, metastatic and/or unresectable, typical or atypical, lung NETs.

Condition or disease Intervention/treatment Phase
Neuroendocrine Tumors in Lung Drug: Lanreotide (Autogel formulation) Drug: Placebo Phase 3

Detailed Description:

As planned initially, a total of 216 eligible patients with well-differentiated typical or atypical, metastatic and/or unresectable lung NETs, and a positive somatostatin receptor imaging (SRI) (Octreoscan® ≥ grade 2 Krenning scale; Ga-PET scan: uptake greater than liver background), had to be randomized 2:1 to either LAN plus BSC (120mg/28 days) or placebo plus BSC following the stratification of 1) typical versus atypical and 2) prior chemotherapy versus no prior chemotherapy*. Due to the premature stop of the recruitment (as per Protocol Amendment #5), 77 patients have been enrolled. All patients still treated in the DB Phase have been entered into the OL Treatment Period (either for follow up or for OL treatment). The transition to the OL treatment period was done by country and per patient, at the following planned scheduled visit (i.e. approximately 28 days from the last injection). Patients enrolled into the study stay on LAN therapy (i.e. OL Treatment Period) until evidence of disease progression (assessed locally and confirmed centrally), development of unacceptable toxicity, or premature withdrawal for any reason or up to 18 months after the last patient randomised. After disease progression patients are followed for survival, QoL and all subsequent anticancer treatments up to the end of the study.

* cytotoxic chemotherapy or molecular targeted therapy or interferon.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 77 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumor Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumors
Actual Study Start Date : February 2016
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : February 2020

Arm Intervention/treatment
Experimental: Lanreotide (Autogel formulation)
120mg every 28 days until disease progression
Drug: Lanreotide (Autogel formulation)
120mg every 28 days until disease progression
Other Names:
  • Lanreotide Depot
  • Somatuline

Placebo Comparator: Placebo
120mg every 28 days until disease progression, then patient may enter open-label treatment with Lanreotide
Drug: Placebo
Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.

Primary Outcome Measures :
  1. Progression-Free Survival (PFS), for subjects randomized in LAN group, assessed by central review using RECIST v1.1 criteria [ Time Frame: From randomisation up to disease progression or up to 18 months (approximately) after the last patient is randomised. ]
    PFS measured by central review using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria, every 12 weeks, defined as the time from randomization to disease progression or death from any causes

Secondary Outcome Measures :
  1. Progression-free survival (PFS), assessed by central review using RECIST v1.1 criteria every 12 weeks, [ Time Frame: From randomization to disease progression or death from any causes during the double-blind phase ]
  2. Progression-free survival (PFS), assessed by local review using RECIST v1.1 criteria every 12 weeks [ Time Frame: From randomization to disease progression or death from any causes during the double-blind phase ]
  3. ORR: objective response rate of CR or PR measured by RECIST v1.1 criteria every 12 weeks [ Time Frame: From randomisation up to the Post Treatment/Early Withdrawal Visit during the double-blind phase ]
  4. Time to treatment failure during the double-blind phase [ Time Frame: From randomisation up to event according to central review or to event according to local review whatever the one which occurs first ]
    Defined as the time from randomization to disease progression using RECIST v1.1, death, consent withdrawn, an AE, protocol deviations, lost to follow-up, the appearance of carcinoid syndrome or other hormone related syndrome necessitating the initiation of SSAs (rescue octreotide and/or LAR SSA), or initiation of anticancer treatment

  5. Mean changes from Baseline in the biomarker chromogranin A (CgA) [ Time Frame: Every 12 weeks thereafter until the post Double-Blind and in the Open Label Extension Treatment Phase ]
  6. Proportion of subjects with a decrease of CgA ≥30% at week 8 in the population of subjects with an elevated CgA (≥2 x ULN) at Baseline [ Time Frame: Double-blind and the Open-label treatment phases ]
  7. Change in Quality of Life (QoL), as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 [ Time Frame: Baseline, week 12, every 12 weeks and at the Post treatment/Early Withdrawal Visit and in the OL Extension Treatment and Follow-up phases ]
  8. Time to QoL deterioration, defined by a decrease from baseline in EORTC Quality of Life Questionnaire C30 (QLQ-C30) score of at least 10 points [ Time Frame: Double-blind, Open-label Treatment and Follow-up phases ]
  9. Mean changes from Baseline in urinary 5-HIAA levels in subjects with elevated urinary 5-hydroxyindoleacetic acid (5-HIAA) (≥2 x Upper limit of normal range) at Baseline [ Time Frame: Every 12 weeks thereafter, and at the Post Treatment/Early Withdrawal Visit and in the Open-label Extension Treatment phase ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have metastatic and/or unresectable pathologically confirmed well-differentiated, typical or atypical neuroendocrine tumor of the lung
  • Histologic evidence of Well differentiated Neuroendocrine tumors (NETs) of the lung (typical and atypical according to the World Health Organisation (WHO criteria), evaluated locally)
  • Has a mitotic index <2 mitoses/2 mm2 for typical carcinoid (TC) and <10 mitoses/2 mm2 and/or foci of necrosis for atypical carcinoid (AC)
  • At least one measurable lesion of the disease on imaging (CT or MRI; RECIST 1.1)
  • Positive Somatostatin receptors (SSTR) imaging

Exclusion Criteria:

  • Poorly differentiated or high grade carcinoma, or patients with neuroendocrine tumors not of lung origin are excluded
  • Has been treated with an Somatostatin analogs (SSA) at any time prior to randomization, except if that treatment was for less than 15 days (e.g. peri-operatively) of short acting SSA or one dose of long acting SSA and the treatment was received more than 6 weeks prior to randomization
  • Has been treated with Peptide receptor radionuclide therapy (PRRT) at any time prior to randomization
  • Has been treated with more than two lines of cytotoxic chemotherapy or molecular targeted therapy or interferon for Lung NET

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02683941

  Hide Study Locations
Layout table for location information
United States, Arizona
Arizona Oncology Associates
Tucson, Arizona, United States, 85711
United States, California
VA Greater Los Angeles
Los Angeles, California, United States, 90073
United States, Colorado
Rocky Mountain Cancer Center
Denver, Colorado, United States, 80218
United States, Louisiana
Ochsner Medical Center
New Orleans, Louisiana, United States, 70112
United States, Massachusetts
Dana-Farber Institute
Boston, Massachusetts, United States, 02215
United States, Michigan
Karmanos Cancer Center
Detroit, Michigan, United States, 48201
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New York
Roswell Park Cancer Center
Buffalo, New York, United States, 14263
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45237
United States, Oregon
Oregon Health and Science Center
Portland, Oregon, United States, 97239
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Texas Oncology
Dallas, Texas, United States, 75246
Texas Oncology-Forth Worth
Fort Worth, Texas, United States, 76104
Klinikum Wels-Grieskirchen GmbH
Wels, Austria, 4600
AKH und Med. University Vienna Allg Krankenhaus Wien
Wien, Austria, 1090
Canada, Alberta
Tom Baker Cancer Center
Calgary, Alberta, Canada, 2TN 4N2
Canada, Nova Scotia
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
McGill University Health Center
Montréal, Quebec, Canada, H4A 3J1
Saskatoon Cancer Centre
Saskatoon, Canada, S7N 4H4
Cancer Care of Manitoba
Winnipeg, Canada, R3E0V9
Aarhus University Hospital
Aarhus, Denmark, 8000
NET-Centre, Rigshospitalet
Copenhagen, Denmark, 2100
Centre Oscar Lambret
Lille, France, 59020
Hôpital Edouard Herriot
Lyon, France, 69437
CLLC, Institut Paoli Calmettes
Marseille, France, 13273
Institut du Cancer de Montpellier (ICM) Val d'Aurelle
Montpellier, France, 34000
CHU de Rennes - Hôpital Pontchaillou
Rennes, France, 35033
Centre René Gauducheau ICO institut de Cancerologie de l'Ouest
Saint-Herblain, France, 44805
Institut Gustave Roussy
Villejuif, France, 94800
Zentralklinik Bad Berka GmbH
Bad Berka, Germany, 99437
Evangelische Lungenklinik Berlin
Berlin, Germany, 13125
Universitätsklinikum Essen (AöR)
Essen, Germany, 45145
Johann Wolfgang Goethe-Universitätsklinikum Frankfurt
Frankfurt, Germany, 60590
Universita di Genova
Genova, Italy, 16132
Insituti Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST)
Meldola, Italy, 47014
Azienda Ospedaliera Antonio Cardarelli
Napoli, Italy, 80131
Azienda Ospedaliera Universitaria di Perugia Santa Maria della Misericordia
Perugia, Italy, 06123
Insittuto Clinico Humanitas
Rozzano, Italy, 20089
Antoni van Leeuwenhoek
Amsterdam, Netherlands
Maastricht University Medical Center
Maastricht, Netherlands
Zakladu Medycyny Nuklearne i Endokrynologii Onkologicznej
Gliwice, Poland, 44-101
University Center of Ophtalmology & Oncology
Katowice, Poland, 40-514
Szpital Uniwersytecki W
Krakow, Poland, 31-501
Szpital Kliniczny im. H. Święcickiego U.M.
Poznan, Poland, 60-355
Warszawa, Poland, 02-348
Hospital Universitari, Vall d'Hebron
Barcelona, Spain, 8035
University Hospital Ramón y Cajal
Madrid, Spain, 28412
Hospital Universitario Marqués de Valdecilla
Santander, Spain, 39008
Hospital Universitario Miguel Servet
Zaragoza, Spain, 50009
United Kingdom
Cancer Center, Beatson Oncology
Glasgow, United Kingdom, G12 0YN
Royal Surrey County Hospital
Guildford, United Kingdom, GU2 7XX
Royal Free Hospital
London, United Kingdom, NW3 2QC
King's College Hospital
London, United Kingdom, SE5 9RS
Christie Hospital
Manchester, United Kingdom, M20 4BX
Churchill Hospital
Oxford, United Kingdom, OX3 7LE
Sponsors and Collaborators
Layout table for investigator information
Study Director: Ipsen Medical Director Ipsen

Layout table for additonal information
Responsible Party: Ipsen Identifier: NCT02683941     History of Changes
Other Study ID Numbers: A-US-52030-328
2015-004992-62 ( EudraCT Number )
First Posted: February 17, 2016    Key Record Dates
Last Update Posted: October 1, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Antineoplastic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs